VYNE Therapeutics Reports $26.5M Net Loss, Enters Merger Agreement with Yarrow Biosciences

VYNE Therapeutics Inc. reported a net loss of $26.5 million for the fiscal year ending December 31, 2025, a significant decrease from the $39.8 million loss recorded in the previous year. The company’s total revenues increased by 13.8% to $570,000, primarily driven by royalty revenues from its agreement with LEO Pharma. Operating expenses also saw a notable decline, with research and development costs dropping by 37.8% to $19.2 million, largely due to the termination of the Phase 2b trial for repibresib gel, which did not meet its primary endpoint. General and administrative expenses decreased by 16% to $11.1 million, reflecting cost-cutting measures implemented during the year.

In a strategic move, VYNE has entered into a merger agreement with Yarrow Biosciences, which is expected to close in the second quarter of 2026, subject to stockholder approval and other customary conditions. This merger will result in Yarrow becoming a wholly owned subsidiary of VYNE, with the combined entity focusing on advancing Yarrow's clinical-stage antibody for Graves' disease. As part of the merger, VYNE plans to declare a special cash dividend of approximately $14.5 million to $16.5 million to its stockholders, further emphasizing its commitment to maximizing shareholder value.

As of December 31, 2025, VYNE had cash, cash equivalents, and marketable securities totaling $29 million, which it believes will be sufficient to fund operations through the anticipated closing of the merger and for at least 12 months thereafter. However, the company acknowledges that it may need to raise additional capital if the merger does not proceed, which could involve diluting existing shareholders or incurring debt. The company has also faced challenges in maintaining compliance with Nasdaq's listing requirements, particularly regarding the minimum bid price for its common stock, which could impact its ability to raise capital in the future.

VYNE's operational focus remains on its product candidates, particularly VYN202, an oral BD2-selective BET inhibitor. The company has faced regulatory hurdles, including a clinical hold on VYN202 due to safety concerns observed in non-clinical studies. Despite these challenges, VYNE is optimistic about the potential of its product pipeline and is exploring strategic alternatives for its other candidates, including repibresib. The company’s future performance will largely depend on the successful execution of its merger with Yarrow and the advancement of its clinical programs.